Latest C-Met Stories
Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL765, a novel small molecule inhibitor of PI3K and mTOR, which are implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy.
Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL147, a novel small molecule inhibitor of phosphoinositide-3 kinase (PI3K), which is implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy.
Aveo Pharmaceuticals has initiated a Phase I clinical trial to evaluate the safety, tolerability and recommended dose of SCH900105, its novel, highly potent antibody to hepatocyte growth factor, administered intravenously in patients with relapsed or refractory solid tumors or lymphoma.
AVEO Pharmaceuticals, Inc., today announced that it has initiated a Phase 1 clinical trial to evaluate the safety, tolerability and recommended dose of SCH900105 (AV-299), its novel, highly potent antibody to hepatocyte growth factor (HGF), administered intravenously in patients with relapsed or refractory solid tumors or lymphoma.
Epistem plc (LSE: EHP), the UK biotechnology and contract research company, will present preclinical results from its recently completed plucked hair biomarker study at the American Association for Cancer Research (AACR) conference, "Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine" in Philadelphia on 23rd September 2008.
US-based drug discovery company Semafore Pharmaceuticals has announced the discovery of novel multi-targeted kinase inhibitors that demonstrated significant anticancer activity in preclinical studies.
DUBLIN, Calif., Aug. 7 /PRNewswire-FirstCall/ -- SuperGen, Inc. , a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that the U.S.
Scientists now have a more complete understanding of how cancer cells send signals to surrounding tissues to promote development of the blood supply needed to support tumor growth. For the first time, it has been shown that signals expressed by tumor cells can directly interact with the outer membrane of adjacent blood vessel cells and influence growth and development.
University of Michigan researchers have figured out one more component in cancer cells' aggressive growth---and hope that knowledge can help kill the cells.
Scientists supported by the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health, have added a key new piece to the puzzle of how tumor cells induce new blood vessels to form and fuel their abnormal growth, a well-known process called angiogenesis.
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.